Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Short-term Objective B  

$23,229,501.04
Fiscal Year: 2010

Green dot: Objective has greater than or equal to the recommended funding.4SB. Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012. IACC Recommended Budget: $75,000,000 over 5 years.

Download 2010 Question 4: Short-term Objective B projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
16p11.2: defining the gene(s) responsible Mills, Alea Cold Spring Harbor Laboratory
A mouse knock-in model for ENGRAILED 2 autism susceptibility Millonig, James University of Medicine & Dentistry of New Jersey
Analysis of cortical circuits related to ASD gene candidates Zador, Anthony Cold Spring Harbor Laboratory
Animal model of speech sound processing in autism Kilgard, Michael University of Texas at Dallas
Animal models of autism: Pathogenesis and treatment Powell, Craig University of Texas Southwestern Medical Center
Animal models of neuropsychiatric disorders Crawley, Jacqueline National Institutes of Health
A novel cell-based assay for autism research and drug discovery Restifo, Linda University of Arizona
A preclinical model for determining the role of AVPR1A in autism spectrum disorders Charles, Rhonda Mount Sinai School of Medicine
Autism iPSCs for studying function and dysfunction in human neural development Loring, Jeanne The Scripps Research Institute
Basal ganglia circuitry and molecules in pathogenesis of motor stereotypy Yang, Xiangdong University of California, Los Angeles
Behavioral and physiological consequences of disrupted Met signaling Levitt, Pat University of Southern California
Caspr2 dysfunction in autism spectrum disorders Robbins, Elissa Yale University
Cellular and genetic correlates of increased head size in autism spectrum disorder Vaccarino, Flora Yale University
Central vasopressin receptors and affiliation Young, Larry Emory University
Central vasopressin receptors and affiliation Young, Larry Emory University
Characterization of a novel mouse model of restricted repetitive behaviors Moy, Sheryl University of North Carolina at Chapel Hill
Characterization of autism susceptibility genes on chromosome 15q11-13 Smith, Stephen Beth Israel Deaconess Medical Center
Characterization of the transcriptome in an emerging model for social behavior Thomas, James Emory University
Cntnap2 in a behavioral model of autism White, Stephanie University of California, Los Angeles
Control of synaptic protein synthesis in the pathogenesis and therapy of autism Kelleher, Raymond Massachusetts General Hospital
Deriving neuroprogenitor cells from peripheral blood of individuals with autism Fujinami, Robert University of Utah
Development of a high-content neuronal assay to screen therapeutics for the treatment of cognitive dysfunction in autism spectrum disorders Bear, Mark Massachusetts Institute of Technology
Dissecting the circuitry basis of autistic-like behaviors in mice Feng, Guoping Massachusetts Institute of Technology
Dissecting the neural control of social attachment Shah, Nirao University of California, San Francisco
Dynamic regulation of Shank3 and ASD Worley, Paul Johns Hopkins University

Objective Cumulative Funding Table

IACC Strategic Plan Objective 2008 2009 2010 2011 2012 Total
Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.

IACC Recommended Budget: $75,000,000 over 5 years
4.5
$15,879,827
42 projects

4.S.B
$20,162,709
70 projects

4.S.B
$23,229,501
92 projects

4.S.B
$21,606,118
89 projects

4.S.B
$21,232,514
94 projects

$102,110,669
4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.

Progress: More than 90 projects were supported to develop animal models.

Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built. The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.